Subcutaneous administration of bortezomib: a new reality in the treatment of patients with multiple myeloma
DOI:
https://doi.org/10.31877/on.2013.22.04Keywords:
Multiple Myeloma, Peripheral Neuropathy, BortezomibAbstract
Subcutaneous administration of bortezomib was approved by EMA in September 2012 for treatment of patients in first-line and relapsed multiple myeloma.
This article update seeks to present the experience of an Autonomous Clinical Oncology Unit at Hospital Fernando Fonseca, EPE, with administration of this new formulation and the results which demonstrated a similarity with the current literature. These results showed the same efficacy as the form of intravenous administration with significant reduction of the occurrence of peripheral
neuropathy which is the main dose-limiting toxicity, compromising the quality of life of these patients.
Downloads
References
(IARC 2013) – Portugal Estimated Cancer Incidence, All Ages: Both Sexes. Acedido em 18.01.2013 em http://globocan.iarc.fr/summary_table_pop.asp
Mohallem, Andréa G. da Costa e Rodrigues, Andrea – Enfermagem Oncológica. São Paulo: Editora Manole, 2007. ISBN 85-204-2209-8
Guimarães, José L. M. & Rosa, Daniela D. – Rotinas em Oncologia. Porto Alegre: Artmed, 2008. ISBN 978-85-363-1168-5
Cashen, Amanda F. et al – The Washington Manual: Hematology and Oncology. Second Edition. Philadelphia: Lippincot Williams &
Wilkins, 2008
Richardson, Paul G et al. Extended Follow-up of a Phase II Trial in Relapsed, Refractory Multiple Myeloma: Final Time-to-Event Results
from the SUMMIT Trial. Cancer 2006; 106 (6): 1316-1319.
Jagannath, S et al. - A Phase 2 Study of Two Doses of bortezomib in Relapses or Refractory Myeloma. Br J Haematol 2004; 127:165-172
(EMA 2013) – Velcade: EPAR – Summary for the public. Acedido em 12.01.2013
em http://www.ema.europa.eu/Find medicine/ Human medicines/ European Public Assessment Reports
RCM – Resumo das Características do Medicamento – Velcade ®, actualizado a 09/2012
Gomes, F. – bortezomib Subcutâneo: Progresso no Tratamento do Mieloma Múltiplo. Revista HematOncologia. Lisboa. Nº19, 2012, p16-17
Moreau, P. et al – Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomized, phase 3, non-inferiority study. The Lancet Oncology. London. Volume12, Issue 5, 2011, p431-440.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Rui Santos
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
(CINAHL Ultimate database)
